Profound Medical (NASDAQ:PROF – Get Free Report) and Sanara MedTech (NASDAQ:SMTI – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.
Earnings & Valuation
This table compares Profound Medical and Sanara MedTech”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Profound Medical | $16.10 million | 12.90 | -$42.57 million | ($0.98) | -5.80 |
| Sanara MedTech | $103.12 million | 3.12 | -$37.56 million | ($3.59) | -9.76 |
Analyst Recommendations
This is a summary of recent ratings and price targets for Profound Medical and Sanara MedTech, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Profound Medical | 1 | 0 | 1 | 1 | 2.67 |
| Sanara MedTech | 1 | 4 | 0 | 0 | 1.80 |
Profound Medical presently has a consensus price target of $11.50, indicating a potential upside of 102.46%. Sanara MedTech has a consensus price target of $35.00, indicating a potential downside of 0.14%. Given Profound Medical’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Profound Medical is more favorable than Sanara MedTech.
Profitability
This table compares Profound Medical and Sanara MedTech’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Profound Medical | -171.57% | -63.03% | -51.24% |
| Sanara MedTech | -29.15% | 29.72% | 2.84% |
Insider & Institutional Ownership
47.9% of Profound Medical shares are held by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are held by institutional investors. 1.5% of Profound Medical shares are held by insiders. Comparatively, 42.0% of Sanara MedTech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Volatility & Risk
Profound Medical has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500. Comparatively, Sanara MedTech has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500.
Summary
Profound Medical beats Sanara MedTech on 8 of the 15 factors compared between the two stocks.
About Profound Medical
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.
About Sanara MedTech
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
Receive News & Ratings for Profound Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Profound Medical and related companies with MarketBeat.com's FREE daily email newsletter.
